Clearside Biomedical to Participate in Two Upcoming Investor Conferences in March 2021
Clearside Biomedical, a biopharmaceutical company focused on vision restoration, will participate in two investor conferences in March 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Clearside Biomedical, a biopharmaceutical company focused on vision restoration, will participate in two investor conferences in March 2021. The first is the Cowen 41st Annual Health Care Conference on March 2, at 2:10 pm ET, focusing on clinical development. The second event is the 33rd Annual ROTH Conference on March 16, at 9:00 am ET, featuring an ophthalmology panel. Both panels will be accessible online, and management will engage in live, virtual one-on-one meetings with registered investors.
Details
News Market Reaction – CLSD
The recorded move for CLSD in the trading session of this news was -7.89%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
ALPHARETTA, Ga., Feb. 23, 2021 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (NASDAQ:CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases, announced today that the Company will participate in two upcoming investor conferences in March 2021:
Cowen 41st Annual Health Care Conference
Blazing New Paths in Clinical Development and Structure Panel
Tuesday, March 2, 2021 at 2:10 pm ET
33rd Annual ROTH Conference
Ophthalmology Panel
Tuesday, March 16, 2021 at 9:00 am ET
The panels will be available for attendees on the conference websites. Management will be participating in live, virtual one-on-one meetings with investors who are registered to attend the conferences.
About Clearside Biomedical
Clearside Biomedical, Inc. is a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve vision for people with serious back of the eye diseases. Clearside’s proprietary SCS Microinjector® targets the suprachoroidal space (SCS®) and offers unique access to the macula, retina and choroid where sight-threatening disease often occurs. The Company’s SCS injection platform is an inherently flexible, in-office, non-surgical procedure, intended to provide targeted delivery to the site of disease and to work with both established and new formulations of medications, as well as future therapeutic innovations. For more information, please visit www.clearsidebio.com.
Investor and Media Contacts:
Jenny Kobin
Remy Bernarda
ir@clearsidebio.com
(678) 430-8206
Source: Clearside Biomedical, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.